Efficacy of a short pretreatment with omalizumab in children with anaphylaxis to hymenoptera venom immunotherapy A report of three cases

Abstract : Hymenoptera venom allergy is the second cause of anaphylaxis in European children.1 Systemic reactions occur in up to 0.8% of schoolchildren. Venom immunotherapy (VIT) is recommended in sensitized children having systemic skin reactions exceeding generalized skin symptoms. VIT carries an 8–20% risk of systemic adverse events.3 Short protocols achieve the maintenance dose faster than conventional protocols but are more frequently associated with anaphylactic reactions. We report the cases of teenagers who experienced severe anaphylactic reactions (SAR) during the rush phase of VIT (Table 1). After an informed consent, a second rush VIT was performed after a pretreatment with omalizumab and was tolerated. No injection of omalizumab was required during the maintenance phase.
Complete list of metadatas

Cited literature [12 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01903058
Contributor : Laurent Jonchère <>
Submitted on : Friday, August 30, 2019 - 4:17:26 PM
Last modification on : Friday, August 30, 2019 - 4:23:41 PM

File

Droitcourt-2018-Efficacy of a ...
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Citation

Catherine Droitcourt, Claude Ponvert, Alain Dupuy, Pierre Scheinmann, Rola Abou-Taam, et al.. Efficacy of a short pretreatment with omalizumab in children with anaphylaxis to hymenoptera venom immunotherapy A report of three cases. Allergology International, Wiley, 2018, 68 (2), pp.268-269. ⟨10.1016/j.alit.2018.09.003⟩. ⟨hal-01903058⟩

Share

Metrics

Record views

74

Files downloads

71